MMP9 and Stroke: Intriguingly, treatment of mouse stroke models with a neutralising human IgG monoclonal antibody, L13 (anti-MMP9), significantly reduces brain tissue injury and improves neurological outcomes of mice when administered at the onset of reperfusion [190].